Ronald E. Blaylock
At a glance: Ronald E. Blaylock is Director at Pfizer (PFE). Their latest SEC Form 4, filed Aug 5, 2026, reported a purchase of $999K. On file: 1 purchase line ($999K) and 0 sale lines ($0).
Disclosed holdings: about $1.9M of PFE stock: 66,938 shares reported on their latest Form 4 (filed Aug 5, 2026), valued at the Nov 19, 2026 close of $27.64. This counts only PFE shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Pfizer Inc (PFE)
Purchase track record
Not enough history. Based on 1 purchase with a full 90 days of price history.
Ronald E. Blaylock's InsiderPrint
3 trades from SEC Form 4 filings, 2020 to 2026, drawn as one fingerprint.
Reading this print: Almost only buys, trading about once a year, typically $499K a trade.
- Bump outward: a purchase (3)
- Dent inward: a sale (0)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Anthony CappellCEO · REFI · 100% match
- Mary Ann S. Sanchez10% Owner · SSP · 99% match
- Michael Mark ManleyCEO · AN · 99% match
- Robert Francis RiversChair · EBC · 99% match
- Tracy W. KrohnCEO, President · WTI · 99% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 5SEC | PFEPfizer IncStake +142% | Buy | 39,23166,938 held (+142%) | $25.46 | $999K | +8.6% |
- Buy
Director Ronald E Blaylock bought $999K of PFE at $25.46 — first open-market purchase in our records; raises the stake by 142%.
Follow Ronald E. Blaylock
Get one email when Ronald E. Blaylock files a new purchase or sale. Free.
At most one email a day about Ronald E. Blaylock, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.